IXICO plc (AIM: IXI), a London-based global leader in neuroscience imaging and biomarker analytics, has announced the development of a new artificial intelligence tool designed to support radiologists in detecting cerebral microbleeds on MRI scans in Alzheimer's disease patients. The research was presented at the 19th Clinical Trials on Alzheimer's Disease Conference 2026 (CTAD) on 17 November 2026. The tool detected approximately 90% of microbleeds in participant scans, comparing favourably to other published results. The development is relevant to investors given the growing clinical demand for vascular safety monitoring as anti-amyloid therapies become more widely used.

Key Points

  • IXICO plc (AIM: IXI) — London-based neuroscience imaging and biomarker analytics company
  • IXICO has developed an AI tool to detect cerebral microbleeds (CMBs) on MRI scans, presented at CTAD 2026
  • The tool detected around 90% of microbleeds per participant scan and performed consistently across studies and imaging techniques
  • Investors may be watching for further clinical adoption or commercial partnerships stemming from this research capability

IXICO's Two-Stage AI Tool Achieves Around 90% Cerebral Microbleed Detection Rate

The newly developed tool operates in two distinct stages: first scanning the whole brain to identify possible microbleeds, then analysing each candidate to distinguish true CMBs from visually similar structures such as blood vessels. According to the announcement, the tool detected around 90% of cerebral microbleeds per participant scan, performing consistently across different studies and MRI imaging techniques. IXICO states this compares favourably to other published results in the field, suggesting the tool may offer a meaningful advancement over current radiologist-led review processes, which the company describes as time-consuming and subject to variability between practitioners.

Vascular Safety Monitoring in Anti-Amyloid Therapy Trials Drives Demand for CMB Detection

Cerebral microbleeds are a key vascular safety concern in Alzheimer's disease clinical trials, particularly in studies involving anti-amyloid therapies. The announcement states that patients receiving these treatments must undergo repeated MRI monitoring for pre-existing and newly arising microbleeds. IXICO's AI tool is positioned to address this monitoring requirement more efficiently and consistently than traditional manual review. As an imaging Contract Research Organisation with a 20-year track record supporting hundreds of neurological clinical trials, IXICO's proprietary IXI platform is already deployed across global trials assessing diseases including Alzheimer's, Huntington's, and Parkinson's.

Chief Scientific Officer Robin Wolz Highlights Accuracy and Consistency Across MRI Techniques

Robin Wolz, Chief Scientific Officer of IXICO, stated in the announcement that as new Alzheimer's treatments become increasingly available, monitoring patient safety accurately and efficiently is more important than ever. He described CMB detection as a critical but time-consuming task subject to inter-radiologist variability. Wolz said the research demonstrates the potential of AI to transform this process, delivering high levels of accuracy and consistency across different MRI techniques and patient populations, adding that this reflects IXICO's application of its neuroscience and AI expertise to real-world drug development challenges.

CTAD 2026 Presentation Underlines IXICO's Role in Alzheimer's Drug Development Ecosystem

The presentation at the 19th Clinical Trials on Alzheimer's Disease Conference 2026 reinforces IXICO's position within the global neurological disease research community. The company operates as an end-to-end imaging CRO, working with leading pharmaceutical companies, biotechs, disease consortia, and non-profit organisations. Having analysed hundreds of thousands of scans and built an expansive network of expert imaging centres worldwide, IXICO's ability to demonstrate reproducible AI performance across heterogeneous datasets represents a sector-specific differentiator. A key risk for the company remains dependency on continued clinical trial activity and pharmaceutical R&D investment in neurological indications.